Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Xcytrin motexafin gadolinium: Phase I/II data

In a dose-escalation Phase I/II trial in 28 patients, Xcytrin plus Zevalin ibritumomab produced a 59%

Read the full 161 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE